- Generic Name:
- Drug Type:
- Monoclonal antibody
- How the Drug is Given:
Indications and Usage
Ofatumumab is FDA approved
- For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
- For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
- In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Side effects needing medical attention
Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.